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A lthough microRNAs are well known for their roles in the regulation of mRNA stability and translation in the cytoplasm, their presence and potential function in the mitochondria have only been recently realized. How specific microRNAs enter the lumen of mitochondria remains unknown. Jagannathan et al 1 now reports that some microR-NAs may even specifically target to different populations of mitochondria in the same cells on diabetic insult, suggesting a potential new disease mechanism, but the finding seems to require further technical and mechanistic refinement.
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MicroRNA was initially detected in the mitochondria during analysis of the mitochondrial transcriptome, and at the time, microRNA was thought to be contaminants of purified mitochondria. 2 However, several later studies based on quantitative polymerase chain reaction analysis and confocal microscopy suggest that the presence of microRNAs in the mitochondria is real. 3, 4 The most vigorous proof is achieved through the nuclease protection assay on purified mitochondria to show that mitochondrial microRNAs (mito-miRs) are insensitive to nuclease treatment even after the outer membrane is stripped, which is an essential step to eliminate contamination of endoplasmic reticulum and other singlemembraned vesicles. 5 These studies open a new chapter in understanding potential role(s) of mito-miRs in development and disease.
Jagannathan et al 1 went further to provide evidence that specific mito-miRs may be targeted to different populations of mitochondria within the same compartment of cardiac muscle. It was initially observed >4 decades ago that cardiomyocytes contain 2 populations of mitochondria, one beneath sarcoplasmic reticulum (called subsarcoplasmic mitochondria) and the other residing between myofibrils (called interfibrillar mitochondria or IFM; Figure) , which could be separately extracted and then purified. 6 Various studies have linked such distinct mitochondria populations to heart failure and other diseases. 7, 8 In this study, using heart from mice insulted with a drug to induce type I diabetes mellitus, the authors isolated those 2 populations of mitochondria using a further improved methodology and then subjected purified small RNA to microarray analysis. Coupled with validation by quantitative polymerase chain reaction, they identified a large number of nuclear genome-derived microRNAs in the mitochondria, some of which seem to be differentially targeted to subsarcoplasmic mitochondria versus IFM on diabetic insult ( Figure) . One in particular, miR-378, was chosen for detailed analysis, as the mito-miR seems to selectively target IFM on diabetes mellitus, despite unaltered total levels in normal and diseased hearts. Because the purification procedure involves Polytron treatment and enzymatic digestion, which may be prone for some unintended artifacts, validation of the data will require in situ analysis by high-resolution microscopy for specific mito-miRs, certain key protein factors involved (such as FXR1, see below), and ideally, functional alternations (such as membrane potential and ROS production) in the affected population of mitochondria in future studies.
Based on bioinformatics prediction, coupled with UV-induced crosslinking of Ago2 (a key component of the RNA-induced silencing complex), the authors went to great lengths to identify mito-miR-378 as a putative regulator of ATP synthase F 0 subunit 6 (ATP6), a mitochondrial encoded protein responsible for transporting H + protons across the inner mitochondrial membrane during aerobic respiration. A reporter-based assay was used to show the ability of miR-378 to target the sequence containing 3 deduced microRNA regulatory elements in transfected HEK293 cells, although it remains unclear that which specific microRNA regulatory element or all are responsible for the observed effect. This experiment would need to be repeated with mutant reporters to help validate the modest base-pairing potential in the seed region of the effective microRNA regulatory element(s).
Interestingly, the authors discovered that, although Ago2 went down in both subsarcoplasmic mitochondria and IFM, the Ago2-associated RNA-binding protein, FXR1, was dramatically increased in IFM on diabetic insult. Concordantly, ATP6 was selectively downregulated at both the transcript and protein levels in IFM of diabetic mice. These observations raised a series of mechanistic questions. First, as both ATP6 mRNA and protein were decreased, it remains to be determined whether decreased mRNA could entirely account for the reduction of protein, and thus, it is unclear whether mito-miR-378 is involved in the regulation of translation, as implied. This question is pertinent to the current study, as FXR1 has been long known for its role in the regulation of mRNA stability, 9, 10 which also begs the question of whether ATP6 mRNA downregulation is mediated by Ago2, FXR1, or both in conjunction with mito-miR-378. Most importantly, it is critical to determine direct versus indirect effects (eg, via some miR-378 targets in the cytoplasm).
Sorting out the mechanistic questions raised above will require a cellular model in which the putative mito-miRmediated effect(s) observed in the heart could be recapitulated. The authors accomplished this on HL-1 cells, observing that transfected miR-378 could indeed downregulate ATP6 mRNA and protein. Although not further pursued, this cellular model would allow for further testing of the regulation at mRNA stability or translation levels and for the functional requirement of Ago2, FXR1, or both in the process. The most challenging question is to differentiate between direct or indirect effect. However, a recent study has been provided a diagnostic criterion for microRNA-mediated function in the cytoplasm versus mitochondria. 5 In this study, it was demonstrated that Ago2, but not GW182 (an essential cofactor of Ago2 in the RNA-induced silencing complex), is present in the mitochondria, which was now further confirmed by Jagannathan et al 1 in this study. Because GW182 is known to be required for microRNA-mediated mRNA decay and translational repression in the cytoplasm, 11 knockdown of GW182 would affect microRNA-mediated functions in the cytoplasm, but not in the mitochondria. This critical experiment remains to be carried out to validate the direct effect of mito-miR-378 in the mitochondria and is also one of the most important functional tests for studying any mito-miR in future studies.
In summary, the findings of Jagannathan et al raise an interesting possibility that diabetic insult may trigger microRNA redistribution among spatially organized mitochondria in cardiac cells, thus suggesting a novel mechanism for diseaseinduced cardiomyopathy. The findings are timely, as we are at the beginning to understand an expanded role of microR-NAs in different cellular compartments, not just the cytoplasm. Although there still remains an array of questions about the function and mechanism of mito-miRs in mitochondria, as addressed above, the authors have established a biological system to study not only just miR-378 but also many other microRNAs that seem to be perturbed in diabetic heart. This opens the door for future studies aimed at characterizing the mechanism of signal-induced uptake of specific mito-miRs into spatially distinct organelles. In addition, because of an apparent improvement of cardiac contractile activity with intraperitoneally injected antagomir-378 reported in the current study, this observation points to an exciting new therapeutic route for treating heart malfunction in patients with diabetics mellitus.
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